fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

FDA provides supplemental approval for Spravato (esketamine) CIII nasal spray, for adults living with major depressive disorder – Johnson & Johnson

Written by | 2 Feb 2025

Johnson & Johnson  announced the FDA approval of a supplemental New Drug Application (sNDA) for Spravato (esketamine) CIII nasal spray, making this innovative treatment the first and only… read more.

Significant funding to ensure personalized treatments that work for rheumatoid arthritis

Written by | 9 Jan 2025

In recent years treatment with powerful biologic and targeted synthetic therapies has changed the landscape for arthritis, but currently finding the right treatment for each person is a… read more.

NICE (UK) recommends teclistamab as an option for treating relapsed and refractory multiple myeloma – Johnson & Johnson

Written by | 1 Dec 2024

NICE (UK) 1.1Teclistamab is recommended as an option for treating relapsed and refractory multiple myeloma in adults, only after 3 or more lines of treatment (including an immunomodulatory… read more.

ASH 2024: Johnson & Johnson showcases innovations in multiple myeloma, B-cell malignancies, and autoimmune disorders

Written by | 21 Nov 2024

Johnson & Johnson announced more than 90 abstracts featuring data from the Company’s differentiated blood cancer portfolio and pipeline will be presented at the 66th American Society of Hematology (ASH)… read more.

European Commission approves expanded use of HIV-1 therapy Edurant (rilpivirine) in younger pediatric patients – Johnson & Johnson

Written by | 6 Nov 2024

Johnson & Johnson announced that the European Commission (EC) has approved Edurant (rilpivirine) for the treatment of HIV-1 infection in adults and children weighing at least 25 kg… read more.

New SPECTREM study findings reveal Tremfya (guselkumab) effectively clears overlooked and undertreated plaque psoriasis – Johnson & Johnson

Written by | 3 Nov 2024

Johnson & Johnson announced that treatment with Tremfya (guselkumab) resulted in clear or almost clear skin in the majority of adults with low body surface area (BSA) moderate… read more.

Johnson & Johnson to present groundbreaking neuropsychiatric research at Psych Congress 2023, featuring advances in depression and schizophrenia treatments

Written by | 25 Oct 2024

Johnson & Johnson announced that 23 abstracts featuring new real-world and clinical trial data from across its neuropsychiatry portfolio and pipeline will be presented at the annual U.S…. read more.

Johnson & Johnson to present 25 abstracts on Generalized Myasthenia Gravis at AANEM and MGFA 2024, featuring promising nipocalimab data

Written by | 18 Oct 2024

Johnson & Johnson announced that 25 abstracts featuring robust research to understand unmet needs in generalized myasthenia gravis (gMG) and evaluate nipocalimab as a potential advanced treatment option… read more.

Johnson & Johnson extended filing at EMA for Darzalex (daratumumab subcutaneous) + R-VDd for newly diagnosed multiple myeloma

Written by | 15 Oct 2024

Janssen-Cilag International NV, a Johnson & Johnson company,  announced the submission of a Type II variation application to the European Medicines Agency (EMA) seeking approval for an indication… read more.

Johnson & Johnson announced that the FDA has approved Tremfya (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis

Written by | 21 Sep 2024

Johnson & Johnson  announced that the FDA has approved Tremfya (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis (UC), a chronic disease of… read more.

Launch of TriLEAP Lower Extremity Anatomic Plating System designed for foot and ankle surgeons – DePuy Synthes (J&J)

Written by | 17 Aug 2024

Johnson & Johnson MedTech announced that DePuy Synthes, The Orthopaedics Company of Johnson & Johnson, has launched its TriLEAP Lower Extremity Anatomic Plating System, a comprehensive system with… read more.

CHMP recommends Yuvanci (macitentan + tadalafil) to treat pulmonary arterial hypertension – Johnson & Johnson

Written by | 5 Aug 2024

The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Yuvanci, intended for the… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.